Phaseline

Targets › ALK7

ALK7 (Activin receptor type-1C): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Feb 2027.

Serine/threonine protein kinase which forms a receptor complex on ligand binding. The receptor complex consists of 2 type II and 2 type I transmembrane serine/threonine kinases. (UniProt, Q8NER5)

Open in Phaseline: the race on ALK7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Arrowhead PharmaceuticalsARO-ALK7
ALK7 activator (activin receptor-like kinase 7 agonist)
ALK7Phase 1ObesityFeb 2027

Conditions

Obesity (1)

Modalities

small molecule (1)

Companies

Arrowhead Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.